[앵커멘트]
Celltrion’s’Rekironaju’, the first Korean-made Corona 19 antibody treatment, was supplied to hospitals in earnest. This is to prevent severe progression, but controversy over efficacy and mutant viruses continues. So Jeong-jin Seo, Honorary Chairman of Celltrion, held a press conference a little while ago and had time to answer these controversies. Let’s connect reporters to see what stories came out. Reporter Seok Ji-heon!
[기사내용]
Celltrion Honorary Chairman Seo Jeong-jin showed the possibility of developing a COVID-19 vaccine.
It was revealed at an online press conference held a while ago.
Chairman Seo said, “If technology sovereignty is a problem, we are ready to advance even to vaccines.”
However, as if they were conscious of the companies currently developing the corona vaccine, they put a clue that “if there is no alternative elsewhere, I will have no choice but to go.”
I also mentioned the mutant virus that has recently spread around the world.
Chairman Seo explained that Rekirona has shown the same efficacy as the existing coronavirus against the virus from the UK.
Regarding the point that Rekirona has no effect on the South African virus, he said it is’in development’.
Chairman Seo said, “Antibody 32 showed strong neutralizing ability against the South African virus. We will secure a variety of antibody pools and develop a suitable platform even if a new virus appears.”
They also strongly dismissed the controversy that the treatment was not effective in general mild patients who were not at high risk.
Rekironaju was only approved for the treatment of patients with high-risk mild symptoms or moderate patients with pneumonia symptoms, not general mild patients as expected.
Seong-Hyun Kim, Head of Clinical Planning for Celltrion, explained, “We have confirmed that the recovery period has decreased by two days even for patients with mild symptoms.”
However, he added, “The Ministry of Food and Drug Safety has limited its use because it made different judgments on whether these effects are appropriate in terms of the economics of the drug.”
This is Jiheon Seok from Money Today broadcast.
Seok Ji-heon, Money Today Broadcasting MTN reporter
If you would like to object to, correct, or request a later report on an article on Money Today, please contact us at the contact information below.
Grievance handler: Content manager[email protected]02)2077-6288